Opposing actions of the progesterone metabolites, 5α-dihydroprogesterone (5αP) and 3α-dihydroprogesterone (3αHP) on mitosis, apoptosis, and expression of Bcl-2, Bax and p21 in human breast cell lines

Journal of Steroid Biochemistry and Molecular Biology

Volumn 118, Issue 1-2, 2010, Pages 125-132

  Wiebe, John P ^a   Beausoleil, Michel ^a   Zhang, Guihua ^a   Cialacu, Valentin ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Apoptosis; Bax; Bcl 2; Breast cancer; Cell proliferation; MCF 10A; MCF 7; MDA MB231; p21; Progesterone metabolites; T47D

Indexed keywords

3ALPHA DIHYDROPROGESTERONE; ANDROSTANOLONE; LIPOCORTIN 5; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; THYMIDINE; TRITIUM;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CARCINOGENESIS; CELL COUNT; CELL PROLIFERATION; CONTROLLED STUDY; DNA FRAGMENTATION; HORMONE ACTION; HORMONE STRUCTURE; HUMAN; HUMAN CELL; MICROENVIRONMENT; MITOSIS; NICK END LABELING; PROTEIN BINDING; PROTEIN EXPRESSION;

20-ALPHA-DIHYDROPROGESTERONE; 5-ALPHA-DIHYDROPROGESTERONE; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAMMARY GLANDS, HUMAN; MITOSIS; PROGESTERONE; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 72449200802     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2009.11.005     Document Type: Article

References (59)

1. Wiebe J.P., Muzia D., Hu J., Szwajcer D., Hill S.A., and Seachrist J.L. The 4-pregnene and 5α-pregnane progesterone metabolites formed in nontumorous and tumorous breast tissue have opposite effects on breast cell proliferation and adhesion. Cancer Res. 60 4 (2000) 936-943
2. Wiebe J.P. Progesterone metabolites in breast cancer. Endocr. Relat. Cancer 13 3 (2006) 717-738
3. Wiebe J.P., and Lewis M.J. Activity and expression of progesterone metabolizing 5α-reductase, 20α-hydroxysteroid oxidoreductase and 3α(β)-hydroxysteroid oxidoreductases in tumorigenic (MCF-7, MDA-MB-231, T-47D) and nontumorigenic (MCF-10A) human breast cancer cells. BMC Cancer 3 (2003) 9
4. Lewis M.J., Wiebe J.P., and Heathcote J.G. Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma. BMC Cancer 4 (2004) 27
5. Wiebe J.P., and Muzia D. The endogenous progesterone metabolite, 5α-pregnane-3,20-dione, decreases cell-substrate attachment, adhesion plaques, vinculin expression, and polymerized F-actin in MCF-7 breast cancer cells. Endocrine 16 1 (2001) 7-14
6. Weiler P.J., and Wiebe J.P. Plasma membrane receptors for the cancer-regulating progesterone metabolites, 5α-pregnane-3,20-dione and 3α-hydroxy-4-pregnen-20-one in MCF-7 breast cancer cells. Biochem. Biophys. Res. Commun. 272 3 (2000) 731-737
7. Wiebe J.P., Lewis M.J., Cialacu V., Pawlak K.J., and Zhang G. The role of progesterone metabolites in breast cancer: potential for new diagnostics and therapeutics. J. Steroid Biochem. Mol. Biol. 93 (2005) 201-208
8. Pawlak K.J., Zhang G., and Wiebe J.P. Membrane 5α-pregnane-3,20-dione (5αP) receptors in MCF-7 and MCF-10A breast cancer cells are up-regulated by estradiol and 5αP and down-regulated by the progesterone metabolites, 3α-dihydroprogesterone and 20α-dihydroprogesterone, with associated changes in cell proliferation and detachment. J. Steroid Biochem. Mol. Biol. 97 3 (2005) 278-288
9. Pawlak K.J., and Wiebe J.P. Regulation of estrogen receptor (ER) levels in MCF-7 cells by progesterone metabolites. J. Steroid Biochem. Mol. Biol. 107 (2007) 172-179
10. Anderson W.A., Perotti M.E., McManaway M., Lindsey S., and Eckberg W.R. Similarities and differences in the ultrastructure of two hormone-dependent and one independent human breast carcinoma grown in athymic nude mice: comparison with the rat DMBA-induced tumor and normal secretory mammocytes. J. Submicrosc. Cytol. 16 4 (1984) 673-690
11. Nardulli A.M., and Katzenellenbogen B.S. Progesterone receptor regulation in T47D human breast cancer cells: analysis by density labeling of progesterone receptor synthesis and degradation and their modulation by progestin. Endocrinology 122 4 (1988) 1532-1540
12. Horwitz K.B., Zava D.T., Thilagar A.K., Jensen E.M., and McGuire W.L. Steroid receptor analyses of nine human breast cancer cell lines. Cancer Res. 38 8 (1978) 2434-2437
13. Soule H.D., Maloney T.M., Wolman S.R., Peterson Jr. W.D., Brenz R., McGrath C.M., Russo J., Pauley R.J., Jones R.F., and Brooks S.C. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 50 18 (1990) 6075-6086
14. Reed J.C. Bcl-2 and the regulation of programmed cell death. J. Cell Biol. 124 1-2 (1994) 1-6
15. Vakkala M., Lahteenmaki K., Raunio H., Paakko P., and Soini Y. Apoptosis during breast carcinoma progression. Clin. Cancer Res. 5 2 (1999) 319-324
16. Luo Y., Hurwitz J., and Massague J. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature 375 6527 (1995) 159-161
17. Abbas T., and Dutta A. P21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer 9 6 (2009) 400-414
18. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 1 (2000) 57-70
19. Wiebe J.P., Souter L., and Zhang G. Dutasteride affects progesterone metabolizing enzyme activity/expression in human breast cell lines resulting in suppression of cell proliferation and detachment. J. Steroid Biochem. Mol. Biol. 100 4-5 (2006) 129-140
20. Wang T.T., and Phang J.M. Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res. 55 12 (1995) 2487-2489
21. Budtz P.E. Role of proliferation and apoptosis in net growth rates of human breast cancer cells (MCF-7) treated with oestradiol and/or tamoxifen. Cell Prolif. 32 5 (1999) 289-302
22. Gompel A., Somai S., Chaouat M., Kazem A., Kloosterboer H.J., Beusman I., Forgez P., Mimoun M., and Rostene W. Hormonal regulation of apoptosis in breast cells and tissues. Steroids 65 10-11 (2000) 593-598
23. Perillo B., Sasso A., Abbondanza C., and Palumbo G. 17β-Estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol. Cell. Biol. 20 8 (2000) 2890-2901
24. Burow M.E., Weldon C.B., Tang Y., McLachlan J.A., and Beckman B.S. Oestrogen-mediated suppression of tumour necrosis factor alpha-induced apoptosis in MCF-7 cells: subversion of Bcl-2 by anti-oestrogens. J. Steroid Biochem. Mol. Biol. 78 5 (2001) 409-418
25. Eigeliene N., Harkonen P., and Erkkola R. Effects of estradiol and medroxyprogesterone acetate on morphology, proliferation and apoptosis of human breast tissue in organ cultures. BMC Cancer 6 (2006) 246
26. Zhang G., Gurtu V., Kain S.R., and Yan G. Early detection of apoptosis using a fluorescent conjugate of annexin V. BioTechniques 23 3 (1997) 525-531
27. Ferguson D.J., and Anderson T.J. Morphological evaluation of cell turnover in relation to the menstrual cycle in the "resting" human breast. Br. J. Cancer 44 2 (1981) 177-181
28. Formby B., and Wiley T.S. Progesterone inhibits growth and induces apoptosis in breast cancer cells: inverse effects on Bcl-2 and p53. Ann. Clin. Lab. Sci. 28 6 (1998) 360-369
29. Ansquer Y., Legrand A., Bringuier A.F., Vadrot N., Lardeux B., Mandelbrot L., and Feldmann G. Progesterone induces BRCA1 mRNA decrease, cell cycle alterations and apoptosis in the MCF7 breast cancer cell line. Anticancer Res. 25 1A (2005) 243-248
30. Horita K., Inase N., Miyake S., Formby B., Toyoda H., and Yoshizawa Y. Progesterone induces apoptosis in malignant mesothelioma cells. Anticancer Res. 21 6A (2001) 3871-3874
31. Formby B., and Wiley T.S. Bcl-2, survivin and variant CD44 v7-v10 are downregulated and p53 is upregulated in breast cancer cells by progesterone: inhibition of cell growth and induction of apoptosis. Mol. Cell. Biochem. 202 1-2 (1999) 53-61
32. Moore M.R., Spence J.B., Kiningham K.K., and Dillon J.L. Progestin inhibition of cell death in human breast cancer cell lines. J. Steroid Biochem. Mol. Biol. 98 4-5 (2006) 218-227
33. Susin S.A., Lorenzo H.K., Zamzami N., Marzo I., Brenner C., Larochette N., Prevost M.C., Alzari P.M., and Kroemer G. Mitochondrial release of caspase-2 and -9 during the apoptotic process. J. Exp. Med. 189 2 (1999) 381-394
34. Kim R., Emi M., and Tanabe K. Role of mitochondria as the gardens of cell death. Cancer Chemother. Pharmacol. 57 5 (2006) 545-553
35. Ghobrial I.M., Witzig T.E., and Adjei A.A. Targeting apoptosis pathways in cancer therapy. CA Cancer J. Clin. 55 3 (2005) 178-194
36. Thomadaki H., and Scorilas A. BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit. Rev. Clin. Lab. Sci. 43 1 (2006) 1-67
37. Dowsett M., Archer C., Assersohn L., Gregory R.K., Ellis P.A., Salter J., Chang J., Mainwaring P., Boeddinghaus I., Johnston S.R., Powles T.J., and Smith I.E. Clinical studies of apoptosis and proliferation in breast cancer. Endocr. Relat. Cancer 6 1 (1999) 25-28
38. Thiantanawat A., Long B.J., and Brodie A.M. Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. Cancer Res. 63 22 (2003) 8037-8050
39. Xie B., Tsao S.W., and Wong Y.C. Sex hormone-induced mammary carcinogenesis in the female Noble rats: expression of bcl-2 and bax in hormonal mammary carcinogenesis. Breast Cancer Res. Treat. 61 1 (2000) 45-57
40. Kandouz M., Lombet A., Perrot J.Y., Jacob D., Carvajal S., Kazem A., Rostene W., Therwath A., and Gompel A. Proapoptotic effects of antiestrogens, progestins and androgen in breast cancer cells. J. Steroid Biochem. Mol. Biol. 69 1-6 (1999) 463-471
41. Balabhadrapathruni S., Santhakumaran L.M., Thomas T.J., Shirahata A., Gallo M.A., and Thomas T. Bis(ethyl)norspermine potentiates the apoptotic activity of the pure antiestrogen ICI 182780 in breast cancer cells. Oncol. Rep. 13 1 (2005) 101-108
42. Fukui M., and Zhu B.T. Mechanism of 2-methoxyestradiol-induced apoptosis and growth arrest in human breast cancer cells. Mol. Carcinog. 48 1 (2009) 66-78
43. Teixeira C., Reed J.C., and Pratt M.A. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res. 55 17 (1995) 3902-3907
44. Matsuoka S., Edwards M.C., Bai C., Parker S., Zhang P., Baldini A., Harper J.W., and Elledge S.J. p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev. 9 6 (1995) 650-662
45. Niculescu III A.B., Chen X., Smeets M., Hengst L., Prives C., and Reed S.I. Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol. Cell. Biol. 18 1 (1998) 629-643
46. Ogryzko V.V., Wong P., and Howard B.H. WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases. Mol. Cell. Biol. 17 8 (1997) 4877-4882
47. Levine A.J. P53, the cellular gatekeeper for growth and division. Cell 88 3 (1997) 323-331
48. Vidal A., and Koff A. Cell-cycle inhibitors: three families united by a common cause. Gene 247 1-2 (2000) 1-15
49. Gartel A.L., and Tyner A.L. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol. Cancer Ther. 1 8 (2002) 639-649
50. Cuevas B.D., Abell A.N., and Johnson G.L. Role of mitogen-activated protein kinase kinase kinases in signal integration. Oncogene 26 22 (2007) 3159-3171
51. Chang L., and Karin M. Mammalian MAP kinase signalling cascades. Nature 410 6824 (2001) 37-40
52. Wada T., and Penninger J.M. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 23 16 (2004) 2838-2849
53. Freeman S.M., and Whartenby K.A. The role of the mitogen-activated protein kinase cellular signaling pathway in tumor cell survival and apoptosis. Drug News. Perspect. 17 4 (2004) 237-242
54. Roberts P.J., and Der C.J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26 22 (2007) 3291-3310
55. Nishizuka Y. The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature 308 5961 (1984) 693-698
56. Swannie H.C., and Kaye S.B. Protein kinase C inhibitors. Curr. Oncol. Rep. 4 1 (2002) 37-46
57. Jarvis W.D., and Grant S. Protein kinase C targeting in antineoplastic treatment strategies. Invest. New Drugs 17 3 (1999) 227-240
58. Wiebe J.P., Dhanvantari S., Watson P.H., and Huang Y. Suppression in gonadotropes of gonadotropin-releasing hormone-stimulated follicle-stimulating hormone release by the gonadal- and neurosteroid 3α-hydroxy-4-pregnen-20-one involves cytosolic calcium. Endocrinology 134 1 (1994) 377-382
59. Beck C.A., Wolfe M., Murphy L.D., and Wiebe J.P. Acute, nongenomic actions of the neuroactive gonadal steroid, 3α-hydroxy-4-pregnen-20-one (3αHP), on FSH release in perifused rat anterior pituitary cells. Endocrine 6 3 (1997) 221-229